Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.5300
-0.0400 (-7.02%)
At close: Nov 20, 2026, 4:00 PM EST
0.6100
+0.0800 (15.09%)
After-hours: Nov 20, 2026, 7:51 PM EST
Biofrontera Revenue
Biofrontera had revenue of $9.07M in the quarter ending September 30, 2026, with 29.79% growth. This brings the company's total for the last twelve months to $48.26M, up 29.85% year-over-year. In the year 2025, Biofrontera had annual revenue of $41.71M with 11.75% growth. That makes Biofrontera the 28,288th largest company in the world by revenue and 3,805th in the United States.
Revenue (ttm)
$48.26M
Revenue Growth
+29.85%
P/S Ratio
0.20
Revenue / Employee
$513,372
Employees
94
Market Cap
9.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.71M | 4.38M | 11.75% |
| Dec 31, 2024 | 37.32M | 3.25M | 9.54% |
| Dec 31, 2023 | 34.07M | 5.40M | 18.82% |
| Dec 31, 2022 | 28.67M | 4.57M | 18.98% |
| Dec 31, 2021 | 24.10M | 5.25M | 27.86% |
| Dec 31, 2020 | 18.85M | -7.33M | -28.01% |
| Dec 31, 2019 | 26.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sonoma Pharmaceuticals | 23.49M |
| cbdMD | 20.93M |
| Universe Pharmaceuticals INC | 17.74M |
| China Pharma Holdings | 4.31M |
| TherapeuticsMD | 3.75M |
| Akanda | 662.47K |
| Optimi Health | 123.70K |
| Incannex Healthcare | 12.00K |
BFRI News
- 8 days ago - Biofrontera Earnings Call Transcript: Q3 2026 - Transcripts
- 8 days ago - Biofrontera Earnings release: Q3 2026 - Filings
- 8 days ago - Biofrontera Quarterly report: Q3 2026 - Filings
- 8 days ago - Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth - GlobeNewsWire
- 15 days ago - Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026 - GlobeNewsWire
- 6 weeks ago - Biofrontera submits sNDA to FDA to expand Ameluz indication - TheFly
- 6 weeks ago - Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body - GlobeNewsWire
- 2 months ago - Biofrontera announces FDA approval of Ameluz supplemental new drug application - TheFly